Home › Gland Pharma › Revenue History

Gland Pharma Revenue History — Quarter by Quarter

Gland Pharma's revenue moved from ₹1,506 Cr in Q1 FY26 to ₹1,743 Cr in Q4 FY26, a 15.7% change over 4 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

Quarter	Revenue (₹ Cr)	YoY Change
Q4 FY26	₹1,743 Cr	+22%
Q3 FY26	₹1,695 Cr	+22%
Q2 FY26	₹1,487 Cr	+6%
Q1 FY26	₹1,506 Cr	+7%

What management said about revenue

Q4 FY26 · FY27 consolidated revenue growth of 12-13% constant currency

Management guided for 12-13% constant currency revenue growth in FY27, driven by new product launches, CDMO ramp-up, and SenXi improvement.

Q3 FY26 · FY27 organic growth of 12-13%

Management expects base business to grow 12-13% in FY27, with potential upside from CDMO contracts and liraglutide US approval.

Q3 FY26 · 5-year organic CAGR of 15%

Company targets 15% organic CAGR over 5 years, excluding inorganic contributions, driven by capacity expansion and CDMO wins.

Q3 FY26 · Synexi annual revenue baseline of €200 million

Synexi's Q3 revenue of €50 million sets a baseline for annualized revenue of ~€200 million, with potential quarterly fluctuations.

Q2 FY26 · FY26 consolidated revenue growth in mid-teens

Management reaffirmed mid-teens percentage revenue growth for FY26, driven by new launches and Senexi improvement.

Q2 FY26 · Senexi EBITDA breakeven in Q3 FY26

Senexi is expected to achieve EBITDA breakeven in Q3 FY26, supported by €50M quarterly revenue target.

Q1 FY26 · Mid-teens revenue growth for FY26

Management expects consolidated revenue to grow in mid-teens for the full year, driven by new product launches and market expansion.

Q1 FY26 · 20M GLP-1 units commercialized in FY27

Management expects to commercialize around 20 million pens/cartridges in FY27 from the expanded capacity.